Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp.'s filings document financial results and operating disclosures for a genomics diagnostics company focused on rare disease testing. Form 8-K reports furnish quarterly and annual results, earnings presentations, preliminary revenue and testing-volume guidance, changes in statement presentation, and modifications to non-GAAP financial measure methodology.
The filing record also covers capital structure and governance matters, including a term loan agreement used to refinance existing debt, Class A common stock and Nasdaq-listed warrant disclosures, board composition changes, and definitive proxy materials. Proxy filings describe director elections, executive compensation, equity awards, stockholder voting matters, and related corporate governance policies.
Insider Trading Activity Report: Eli Casdin, Director and 10% owner of GeneDx Holdings (WGS), reported multiple transactions on June 18, 2025. The transactions involved Restricted Stock Units (RSUs) and Class A Common Stock:
- Acquired 3,576 new RSUs that vest at the earlier of next annual meeting or first grant anniversary
- Converted 12,924 RSUs into Class A Common Stock at $0 exercise price
- Currently holds beneficial ownership of: - 20,518 shares directly - 3,507,164 shares through Casdin Partners Master Fund - 19,247 shares through Casdin Partners GP - 333,144 shares through CMLS Holdings
The filing indicates significant insider ownership through various investment vehicles, with Casdin maintaining substantial control through multiple entities where he serves in management positions. The transaction was reported within the required timeframe through an attorney-in-fact.
Keith A. Meister, Director and 10% Owner of GeneDx Holdings, reported multiple transactions in company securities on June 18, 2025:
- Acquired 12,924 shares of Class A Common Stock through the conversion of Restricted Stock Units (RSUs) at $0 cost
- Received a new grant of 3,576 RSUs that will vest at the earlier of next annual shareholder meeting or first grant anniversary
- Following transactions, directly owns 20,129 shares and indirectly controls 3,674,913 shares
Indirect ownership includes 333,144 shares through CMLS Holdings LLC, where Meister serves on Board of Managers, and 3,341,769 shares through Corvex Management LP, where he controls the general partner. The transactions demonstrate continued insider investment aligned with long-term shareholder interests.
Director Jason Ryan of GeneDx Holdings reported multiple transactions in Class A Common Stock on June 18, 2025:
- Acquired 12,924 shares through the conversion of Restricted Stock Units (RSUs) at $0 cost, resulting in direct ownership of 13,054 shares
- Received a new grant of 3,576 RSUs that will vest at the earlier of next annual shareholder meeting or first grant anniversary
- Maintains indirect ownership of 141,356 shares through the Jason Ryan 2024 GRAT
The RSUs represent a contingent right to receive one share of Class A Common Stock upon settlement without consideration. The filing demonstrates continued equity-based compensation for board service and significant insider ownership through both direct holdings and a grantor retained annuity trust structure.